Substance / Medication

Bortezomib

Overview

Active Ingredient
bortezomib
RxNorm CUI
358258
Labeler: Ningbo Shuangcheng Pharmaceutical Co., Ltd.Updated: 2025-12-30T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Adverse Reactions (6.1) [see] Bortezomib for Injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions. Bortezomib for Injection is contraindicated for intrathecal administration. F

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

23 trials linked to this intervention

23
Total Trials
13
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single-centre retrospective cohort and systematic literature review.
Lee Nicholas C J, Yates Sean, Rambally Siayareh et al. · Br J Haematol · 2024
PMID: 37571963Meta-Analysis
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
Ding Kaixi, Jiang Wei, Jia Huanan et al. · Biomolecules · 2022
PMID: 36358997Meta-AnalysisFull text (PMC)
Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
Dinoto Alessandro, Cheli Marta, Bratina Alessio et al. · J Neuroimmunol · 2021
PMID: 33975246Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bortezomib (substance)
SNOMED CT
407097007
UMLS CUI
C1176309
RxNorm CUI
358258
Labeler
Ningbo Shuangcheng Pharmaceutical Co., Ltd.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
23
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.